CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup anal…
DOI 10.1055/s-0045-1810977
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Kröcher, J Heo, T Okusaka, J-H Yoon, B Sangro, S L Chan, J P Erinjeri, M Matos, T Decaens, E X Chen, M S Beg, A M Matilla, LT T Phuong, R Griffin, S I Udoye, S Indiviglio, M Kudo
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e551
Kernaussage aus der Literatur
Abstract-Vorschau
Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis
Zitieren
Zitierempfehlung
A Kröcher, J Heo, T Okusaka, J-H Yoon, B Sangro, S L Chan, J P Erinjeri, M Matos, T Decaens, E X Chen, M S Beg, A M Matilla, LT T Phuong, R Griffin, S I Udoye, S Indiviglio, M Kudo (2025) Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis. Zeitschrift für Gastroenterologie, 63 (08), e551. https://doi.org/10.1055/s-0045-1810977
Mit CareLit weiterarbeiten